Bookmark and Share

Publications - Vibrio Cholerae

Young CR, Levine MM, Craig JP, Robins-Browne R. Microtiter enzyme-linked immunosorbent assay (ELISA) for IgG cholera antitoxin in man. I. Method and correlation with rabbit skin vascular permeability factor technique. Infect. Immun. 1980;27:492-496.

Robins-Browne RM, Young CR, Levine MM, Craig JP. Microtiter enzyme-linked immunosorbent assay (ELISA) for IgG cholera antitoxin in man. II. Sensitivity and Specificity. Infect. Immun. 1980;27:497-500.

Levine MM. Cholera in Louisiana: old problem, new light. (Editorial), N. Eng. J. Med. 1980;302:345-347.

Rennels MB, Levine MM, Daya V, Angle P, Young C. Selective vs. non-selective media and direct plating vs. enrichment technique in isolation of Vibrio cholerae: recommendations for clinical laboratories. J. Infect. Dis. 1980;142:328-331.

Levine MM, Black RE, Clements ML, Cisneros L, Nalin DR, Young CR. The quality and duration of infection-derived immunity to cholera. J. Infect. Dis. 1981;143:818-820.

Morris, JG, Wilson, R, Davis, BR, Wachsmuth, IK, Riddle, CF, Wathen, HG, Pollard, RA, Blake, PA, Non-01 Vibrio cholerae gastroenteritis in the United States: clinical, epidemiologic, and laboratory characteristics of sporadic cases. Ann. Intern. Med. 1981;94:656-658.

Wilson R, Lieb S, Roberts A, Stryker S, Janowski H, Gunn RA, Davis B, Barrett T, Morris JG, Blake PA. Non-0 group 1 Vibrio cholerae gastroenteritis associated with eating raw oysters. Am. J. Epidemiol., 1981;114:293-298.

Levine MM, Young CR, Hughes TP, O'Donnell S, Black RE, Clements ML, Robins-Browne T, Lim YL. Duration of serum antitoxin response following Vibrio cholerae infection in North Americans: relevance for seroepidemiology. Am. J. Epidemiol. 1981;114:348-354.

Levine MM, Kaper JB. The significance of Vibrio cholerae in the United States. Clin. Microbiol. Newsletter. 1981;3:162-164.

Snyder JD, Allegra DT, Levine MM, Craig JP, Feeley JC, DeWitt WE, Blake PA. Serologic Studies of Naturally Acquired Infection with Vibrio cholerae O Group 1 in the United States. J. Infect. Dis. 1981;143:182-187.

Clements ML, Levine MM, Young CR, Black RE, Lim YL, Robins-Browne RM, Craig JP. Magnitude, Kinetics and Duration of Vibriocidal Responses in North Americans following ingestion of Vibrio cholerae. J. Infect. Dis. 1982;145:465-473.

Levine MM, Black RE, Clements ML, Cisneros L, Saah A, Nalin DR, Gill MD, Craig JP, Young CR, Ristaino R. Pathogenicity of non-enterotoxigenic Vibrio cholerae El Tor isolated from sewage water in Brazil. J. Infec. Dis. 1982;145:296-299.

Huang CTL, Levine MM, Daoud GS, Nalin DR, Nichols BL. Fecal steroids in diarrhea. IV. Cholera. Lipids. 1982;17:612-616.

Morris JG, Echeverria PD, West GR, Holck SE, Karaulnik M, Blake PA. Cholera among refugees in Rangsit, Thailand. J. Infect. Dis. 1982;145:131-134.

Levine MM, Black RE, Clements ML, Young CR, Lanata C, Sears S, Honda T, Finkelstein R. Texas Star-SR: Attenuated Vibrio cholerae Oral Vaccine Candidate. Develop. Biol. Standard. 1983;53:59-65.

Lockman H, Kaper JB. Nucleotide Sequence Analysis of the A2 and B Subunits of Vibrio cholerae Enterotoxin. J. Biol. Chem. 1983;258:13722-13726.

Kaper JB, Lockman H, Baldini MM, Levine MM. Recombinant Nontoxigenic Vibrio cholerae Strains as Attenuated Cholera Vaccine Candidates. Nature 1984;308:655-658.

Levine MM, Black RE, Clements ML, Lanata C, Sears S, Honda T, Young CR, Finkelstein RA. Evaluation in Man of Attenuated Vibrio cholerae El Tor Ogawa Strain Texas Star-SR as a Live Oral Vaccine. Infect. Immun. 1984;43:515-522.

Kaper JB, Lockman H, Baldini MM, Levine MM. Recombinant live oral cholera vaccine. Biotechnology 1984;2:345-349.

Morris JG, Picardi JL, Lieb S, Lee JV, Roberts A, Hood M, Gunn RA, Blake PA. Isolation of non-toxigenic Vibrio cholerae 0-group 1 from a case of severe gastrointestinal disease. J. Clin. Microbiol., 1984;19:296-297.

Sears SD, Richardson K, Young C, Parker CD, Levine MM. Evaluation of the human response to outer membrane oroteins of Vibrio cholerae. Infect. Immun. 1984;4:439-444.

O'Brien AD, Chen ME, Holmes RK, Kaper J, Levine MM. Environmental and human isolates of Vibrio cholerae and Vibrio parahaemolyticus produce a Shigella dysenteriae 1 (Shiga)-like cytotoxin. Lancet 1984;I:77-78.

Svennerholm AM, Levine MM, Holmgren J. Weak serum and intestinal antibody responses to Vibrio cholerae soluble hemagglutinin in cholera patients. Infect. Immun. 1984;45:792-794.

Hirst, TR, Sanchez J, Kaper JB, Hardy SJS, Holmgren J. Mechanism of toxin secretion by Vibrio cholerae investigated in strains harboring plasmids that encode Escherichia coli's heat-labile enterotoxins. Proceedings of the National Academy of Science, USA, 1984;81:7752-7756.

Lockman, HA, Galen JE, Kaper JB. Further analysis of the Vibrio cholerae Enterotoxin Genes: Nucleotide sequence analysis of the gene encoding the ADP-ribosylating subunit. J. Bacteriol. 1984;159:1086-1089.

Pierce NF, Kaper JB, Mekalanos JJ, Cray WC, Jr. Role of cholera toxin in enteric colonization by Vibrio cholerae 01 in rabbits. Infect. Immun. 1985;50:813-816.

Kaper JB, Nataro JP, Roberts NC, Siebeling RJ, Bradford HB. Molecular epidemiology of non-01 Vibrio cholerae and V. mimicus in the U.S. Gulf Coast region. J. Clin. Microbiol. 1986;23:652-654.

Lin FYC, Morris JG, Kaper JB, Gross T, Michalski J, Morrison C, Libonati JP, Israel E. Persistence of cholera in the United States: Isolation of Vibrio cholerae 01 from a patient with diarrhea in Maryland. J. Clin. Microbiol. 1986;23:624-626.

Richardson K, Michalski J, Kaper JB. Hemolysin production and cloning of two hemolysin determinants from classical Vibrio cholerae. Infection and Immunity, 1986;54:415-420.

Honda T, Nishibuchi M, Miwatani T, Kaper JB. Demonstration of a plasmid-borne gene expressing a thermostable direct hemolysin in Vibrio cholerae non-01 strains. Appl. Environ. Microbiol. 1986;52:1218-1220.

Pierce NF, Kaper JB, Mekalanos JJ, Cray WC Jr., Richardson K. Determinants of the immunogenicity of live virulent and mutant Vibrio cholerae 01 in rabbit intestine. Infect. Immun. 1987;55:477-481.

Levine MM, Kaper JB, Herrington D, Losonsky G, Morris JG, Clements ML, Black RE, Tall B, Hall R. Volunteer studies of deletion mutants of Vibrio cholerae 01 prepared by recombinant techniques. Infect. Immun. 1988;56:161-167.

Pierce NF, Cray WC Jr., Kaper JB, Mekalanos JJ. Determinants of immunogenicity and mechanisms of protection by virulent and mutant Vibrio cholerae 01 in rabbits. Infection and Immunity, 1988;56:142-148.

Hall RH, Vial PA, Kaper JB, Mekalanos JJ, Levine MM. Morphological studies on fimbriae expressed by Vibrio cholerae 01. Microbial Pathogenesis 1988;4:257-265.

Finch, MJ, Morris, JG, Kaviti, J, Kagwanja, W, Levine, MM. Molecular epidemiology of antimicrobial-resistant cholera in Kenya and East Africa. Am. J. Trop. Med. Hygiene 1988, 39, 484-490

Nair GB, Oku Y, Takeda Y, Ghosh A, Ghosh RK, Chattopadyay S, Pal SC, Kaper JB, Takeda T. Toxin profiles of Vibrio cholerae non-01 from environmental sources in Calcutta, India. Appl. Environ. Microbiol. 1988;54:3180-3182.

Levine MM, Kaper JB, Herrington D, Losonsky GA, Tacket CO, Tall B. The current status of cholera vaccine development and experience with cholera vaccines trials in volunteers. Southeast Asian J Trop Med Pub Health, 1988;19:401-415.

Levine MM, Kaper JB, Herrington D, Ketley J, Losonsky G, Tacket CO, Tall B, Cryz S. Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR. Lancet, 1988;ii:467-470.

Vimr ER, Lawrisuk L, Galen J, Kaper JB. Cloning and expression of the Vibrio cholerae neuraminidase gene nanH in Escherichia coli. J. Bacteriol. 1988;170:1495-1504.

Herrington DA, Hall RH, Losonsky G, Mekalanos JJ, Taylor RK, Levine MM. Toxin, toxin co-regulated pili and the toxR regulon are essential for Vibrio cholerae pathogenesis in humans. J. Exp. Med. 1988;168:1487-1492.

Richardson K, Kaper JB, Levine MM. Human immune response to Vibrio cholerae whole cells and isolated outer membrane antigens. Infect. Immun. 1989;57:495-501.

Roggentin P, Rothe B, Kaper JB, Galen J, Lawrisuk L, Vimr ER, Schauer R. Conserved sequences in bacterial and viral sialidases. Glycoconjugate 1989;6:349-353.

Migasena S, Pitisuttitham P, Prayurahong B, Suntharasamai P, Supanaranond W, Desakorn V, Vongsthongsril U, Tall B, Ketley J, Losonsky G, Cryz S, Kaper JB, Levine MM. Preliminary Assessment of the Safety and Immunogenicity of Live Oral Cholera Vaccine Strain CVD 103-HgR in Healthy Thai Adults. Infect. Immun. 1989;57:3261-3264.

Morris JG, Takeda T, Tall BD, Losonsky GA, Bhattacharya SK, Forrest BD, Kay BA, Nishibuchi M. Experimental non-O group 1 Vibrio cholerae gastroenteritis in humans. J. Clin. Invest. 1990;85:697-705.

Clemens JD, Sack DA, Chakraborty J, Rao MR, Ahmed F, Harris JR, Van Loon F, Khan MR, Yunis M, Huda S. Field trial of oral cholera vaccines in Bangladesh: evaluation of anti-bacterial and anti-toxic breast milk immunity in response to ingestion of the vaccines. Vaccine 1990;8:469-472.

Clemens JD, Sack DA, Harris JR, Khan MR, Chakraborty J, Chowdhury S, Rao MR, Van Loon F, Stanton BF, Yunus M. Breast feeding and the risk of severe cholera in rural Bangladesh children. Amer. J. Epidemiol. 1990;131:400-411.

Clemens JD, Sack DA, Harris JR, Van Loon F, Chakraborty J, Ahmed F, Rao MR, Khan MR, Yunus M, Huda N. Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up. Lancet 1990;335:270-273.

Cryz SJ, Levine MM, Kaper JB, Furer E, Althaus B. Randomized double-blind placebo-controlled trial to evaluate the safety and immunogenicity of the live oral cholera vaccine strain CVD 103-HgR in adult swiss. Vaccine 1990;8:577-580.

Hall RH, Drasar BS. Vibrio cholerae H1yA hemolysin is processed by proteolysis. Infect. Immun. 1990;58:3375-3379.

Hoge CW, Sethbatur O, Bodhidatta L, Echeverria P, Robertson DC, Morris JG. Use of a synthetic oligonucleotide probe to detect strains of non-O1 V. cholerae carrying the gene for heat stable enterotoxin (NAG-ST). J. Clin. Microbiol. 1990;28:1473-6.

Kaper JB, Levine MM. Recombinant attenuated Vibrio cholerae strains used as live oral vaccines. Res. Microbiol. 1990;141:901-906.

Ketley JM, Kaper JB, Herrington DA, Losonsky GA and Levine MM. Diminished immunogenicity of a recombination-deficient derivative of Vibrio cholerae vaccine strain CVD 103. Infection and Immunity 1990;58:1481-1484.

Marcus H, Ketley JM, Kaper JB and Holmes RK. Effects of DNase production, plasmid size and restriction barriers on transformation of Vibrio cholerae by electroporation and osmotic shock. FEMS Microbiol. Lett. 1990;68:149-154.

Morris JG Jr. Non-0 Group 1 Vibrio cholerae: a look at the epidemiology of an occasional pathogen. Epidemiol. Rev. 1990;12:179-191.

Morris JG Jr, Takeda T, Tall BD, Losonsky GA, Bhattacharya SK, Forrest BD, Kay BA, Nishibuchi M. Experimental non-O group 1 Vibrio cholerae gastroenteritis in humans. J. Clin Investig. 1990;85:697-705.

Nishibuchi DM, Khaeomanee-iam V, Honda T, Kaper JB and Miwatani T. Comparative analysis of the hemolysin genes of Vibrio cholerae non-01, V. mimicus, and V. hollisae that are similar to the tdh gene of V. parahaemolyticus. FEMS Microbiol. Lett. 1990;67:251-256.

Panigrahi P, Tall BD, Russell RG, Morris JG. Development of an in vitro model for study of non-O1 Vibrio cholerae virulence using Caco-2 cells. Infect. Immun. 1990;58:3415-24.

Richardson K, Nixon L, Mostow P, Kaper JB, Michalski J. Transposon-induced non-motile mutants of Vibrio cholerae. J. Gen. Microbiol. 1990;136:717-725.

Tacket CO, Forrest B, Morona R, Attridge SR, LaBrooy J, Tall BD, Reymann M, Rowley D, Levine MM. Safety, immunogenicity, and efficacy against cholera challenge in man of a typhoid-cholera hybrid vaccine derived from Salmonella typhi Ty21a. Infect. Immun. 1990;58:1620-1627.

Van Loon FP, Clemens JD, Shahrier M, Sack DA, Stephensen CB, Khan MR, Rabbani GH, Rao MR, Banik AK. Low gastric acid as risk factor for cholera transmission: application of a new non-invasive gastric acid field test. J. Clin Epidemiol. 1990;42:1361-1367.

Fasano A, Baudry-Maurelli B, Pumplin DW, Wasserman SS, Tall BD, Ketley JM, Kaper JB. Vibrio cholerae produces a second enterotoxin which affects intestinal tight junctions. Proc. Nat. Acad. Sci, USA 1991;88:5242-5246.

Hall R, Losonsky G, Silveira APD, Taylor RK, Mekalanos JJ, Levine MM. Toxin coregulated pili, an essential colonization factor of Vibrio cholerae O1, are not immunogenic in humans. Infect. Immun. 1991;59:2508-2512.

Lind CD, Davis RH, Guerrant RL, Kaper JB, Mathias JR. Effects of Vibrio cholerae recombinant strains on rabbit ileum in vivo. Enterotoxin production and myoelectric activity. Gastroenterology 1991;101:319-324.

Baudry B, Fasano A, Ketley J, Kaper JB. Cloning of a gene (zot) encoding a new toxin produced by Vibrio cholerae. Infect Immun 1992;60:428-434.

Cryz SJ, Levine MM, Losonsky G, Kaper JB, Althaus B. Safety and immunogenicity of a booster dose of Vibrio cholerae CVD 103-HgR live oral cholera vaccine in Swiss adults. Infect Immun 1992;60:3916-3917.

Galen JE, Ketley JM, Fasano A, Richardson SH, Wasserman SS, Kaper JB. Role of Vibrio cholerae neuraminidase in the function of cholera toxin. Infect Immun 1992;60:406-415.

Johnson JA, Panigrahi P, Morris JG. Non-O1 Vibrio cholerae NRT36S produces a polysaccharide capsule that determines colony morphology, serum resistance, and virulence in mice. Infect Immun 1992;60:864-869.

Kaper JB, Srivastava BS. Genetics of cholera toxin. Indian J Med Res 1992;95:163-167.

Kotloff KL, Wasserman SS, O'Donnell S, Losonsky GA, Cryz SJ, Levine MM. Safety and immunogenicity in North Americans of a single dose of live oral cholera vaccine CVD 103-HgR: results of a randomized, placebo-controlled, double-blind crossover trial. Infect Immun 1992;60:4430-4432.

Rice EW, Johnson CJ, Clark RM, Fox KR, Reasoner DJ, Dunnigan ME, Panigrahi P, Johnson JA, Morris JG. Chlorine and survival of "rugose" Vibrio cholerae. (letter) Lancet 1992;340:740.

Russell RG, Tall BD, Morris JG. Non-O1 Vibrio cholerae pathology and invasion in the removable intestinal tie-adult rabbit diarrhea (RITARD) model. Infect Immun 1992;60:435-442.

Su-Arehawaratana P, Singharaj P, Taylor DN, Hoge C, Trofa A, Kuvanont K, Migasena S, Pitisuttiham P, Lim YL, Losonsky G, Kaper JB, Wasserman SS, Cryz S, Echeverria P, Levine MM. Safety and immunogenicity of different immunization regimens of CVD 103-HgR live oral cholera vaccine in soldiers and civilians in Thailand. J. Infect. Dis. 1992;165:1042-1048.

Suharyono C, Simanjuntak N, Witham N, Punjabi D, Heppner G, Losonsky G, Totosudirjo H, Rifai AR, Clemens J, Burr D, Wasserman SS, Kaper JB, Sorenson K, Cryz S, Levine MM. Safety and immunogenicity of a single-dose live oral cholera vaccine CVD 103-HgR in 5-9 year-old Indonesian children. Lancet 1992:340:689-694.

Tacket, CO, Losonsky G, Nataro JP, Cryz SJ, Edelman R, Kaper JB, Levine MM. Onset and duration of protective immunity in challenged volunteers after vaccination with live oral cholera vaccine CVD 103-HgR. J. Infect. Dis. 1992;166:837-841.

Wright AC, Guo Y, Johnson JA, Nataro JP, Morris JG Development and testing of a non-radioactive DNA oligonucleotide probe that is specific for Vibrio cholerae cholera toxin. J Clin Microbiol 1992;30:2302-2306.

Wasserman SS, Kotloff KL, Losonsky GA, Levine MM. Immunologiv response to oral cholera vaccination in a crossover study: a novel placebo effect. Am J Epidemiol 138:988-993, 1993.

Lagos R, Avendaño A, Horwitz I, Prado V, Ferreccio C, Sotomayor V, Losonsky G, Wasserman SS, Cryz S, Kaper JB, Levine MM. Tolerance and immunogenicity of an oral dose of CVD 103-HgR: a double blind study in Chilean adults. Revista Médica de Chile, 1993, 121:857-863.

Gotuzzo E, Butron B, Seas C, Penny M, Ruiz R, Losonsky G, Lanata D, Wasserman S, Salazar E, Kaper J, Cryz S, Levine M. The safety, immunogenicity and excretion pattern of single-dose live oral cholera vaccine, CVD 103-HgR in Peruvian adults of high and low socioeconomic level. Infect Immun 61:3994-3997, 1993.

Trucksis, M., J.E. Galen, J. Michalski, A. Fasano, and J.B. Kaper. Accessory cholera enterotoxin (Ace), the third toxin of a Vibrio cholerae virulence cassette. Proc. Natl. Acad. Sci. USA 1993; 90:5267-5271.

Tacket CO, Losonsky G, Nataro JP, Cryz, SJ, Edelman R, Fasano A, Michalski J, Kaper JB, Levine MM. Safety, Immunogenicity, and Transmissibility of Live Oral Cholera Vaccine Candidate CVD 110, )ctxA )zot )ace Derivative of El Tor Ogawa Vibrio cholerae. Journal of Infectious Diseases, 1993, 168, 1536-1540.

Rice, EW, Johnson, CH, Clark, RM, Fox, KR, Reasoner, DJ, Dunnigan, ME, Panigrahi, P, Johnson, JA, Morris, JG. Vibrio cholerae O1 can assume a "rugose" survival form that resists killing by chlorine, yet retains virulence. Int. J. Environ. Health Res. 1993, 3 , 89-98.

Simanjuntak C, O'Hanley P, Punjabi N, Noriega F, Pazzaglia G, Dykstra P, Kay B, Suharyono, Rifai AR, Wasserman SS, Losonsky G, Kaper J, Cryz S, Levine MM. The safety, immunogenicity and transmissibility of single-dose live oral cholera vaccine CVD 103-HgR in 25 to 59 month old indonesian children. J. Infect. Dis. 1993;168:1169-1176.

Sinha VB, A Jacob, R Srivastava, JB Kaper, BS Srivastava. Identification of the Flagellar Antigens of Vibrio cholerae El Tor and Their Role in Protection. Vaccine. 1993, 11:372-375.

Losonsky GA, Tacket CO, Wasserman SS, Kaper JB, Levine MM. Secondary Vibrio cholerae-specific cellular antibody responses following wild-type homologous challenge in people vaccinated with CVD 103-HgR live oral cholera vaccine: changes with time and lack of correlation with protection. Infect Immun 61:729-733, 1993.

Michalski, J., J.E. Galen, A. Fasano, and J.B. Kaper. CVD110, an attenuated Vibrio cholerae O1 El Tor live oral vaccine strain. Infect. Immun. 1993; 61:4462-4468.

Jacob, A., V.B. Sinha, M.K. Sahib, R. Srivastava, J.B. Kaper, B.S. Srivastava. Identification of a 33 kDa antigen associated with an adhesive and colonizing strain of Vibrio cholerae El tor and its role in protection. Vaccine. 1993,11:376-382.

Johnson JA, Morris JG, Kaper JB. Gene encoding zonula occludins toxin (zot) does not occur independently from cholera enterotoxin genes (ctx) in Vibrio cholerae. J. Clin. Microbiol. 1993, 31, 732-733.

Cryz SJ Jr., Levine MM, Losonsky GA, Kaper JB, Althaus B. Safety and immunogenicity of a booster dose of Vibrio cholerae CVD 103-HgR live oral cholera vaccine in Swiss adults. Infect Immun 60:3916-3917, 1993.

Ketley JM, Michalski J, Galen J, Levine MM, Kaper JB. Construction of genetically-marked Vibrio cholerae 01 vaccine strains. FEMS Microbiol Lett 111:15-22, 1993.

Faruque, S.M., L. Comstock, J.B. Kaper, and M. J. Albert. Prevalence of zonula occludens toxin (zot) Gene Among Clinical Isolates of Vibrio cholerae 01 from Bangladesh and Africa. J. Diarrhoeal Dis. Res., 1994, 12:222-224..

Johnson, J.A., Salles, C.A., Panigrahi, P., Albert, M.J., Wright, A.C., Johnson, R.J., Morris, J.G. Vibrio cholerae O139 synonym Bengal is closely related to Vibrio cholerae El Tor, but has important differences. Infect. Immun. 1994, 62, 2108-10.

Kaper, J.B., J. Michalski, J.M. Ketley, and M.M. Levine. Potential for Reacquisition of Cholera Enterotoxin Genes by Attenuated Vibrio cholerae Vaccine Strain CVD 103-HgR. Infection and Immunity. 1994, 62:1480-1483.

Kumar, K.K., R. Srivastava, V.B. Sinha, J.B. Kaper, and B.S. Srivastava. Effect of recA Mutation on Vibrio cholerae Adherence and Colonization. Microbiology (Journal of General Microbiology). 1994, 140:1217-1222.

Wasserman SS, Losonsky GA, Noriega F, Tacket CO, Castaneda E, Levine MM. Kinetics of the vibriocidal antibody response to live oral cholera vaccine. Vaccine 12:1000-1003, 1994.

Comstock, LE, Maneval, D, Jr., Panigrahi, P, Joseph, A, Levine, MM, Kaper, JB, Morris, JG, Johnson, JA. Capsule and O antigen in Vibrio cholerae O139 Bengal are associated with a genetic region not present in Vibrio cholerae O1. Infect. Immun. 1995, 63, 317-323.

Cryz SJ Jr, Que JU, Levine MM, Wiedermann G, Kollaritsch H. Safety and immunogenicity of a live oral bivalent typhoid fever (Salmonella typhi-Ty21a) cholera (Vibrio cholerae CVD 103-HgR) vaccine in healthy adults. Infect Immun 63:1336-1339, 1995.

Lagos R, Avendaño A, Prado V, Horwitz I, Wasserman S, Losonsky G, Cryz S, Kaper JB, Levine MM. Attenuated live cholera vaccine strain CVD 103-HgR elicits significanlty higher serum vibriocidal antibody titers in persons of blood group O. Infection and Immunity, 1995, 63:707-709.

Morris JG, Losonsky GA, Johnson JA, Tacket CO, Nataro JP, Panigrahi P, Levine MM. Clinical and immunologic characteristics of Vibrio cholerae O139 Bengal infection in North American volunteers. Journal of Infectious Diseases, 1995, 171, 903-908.

Prado V, Cordero J, Garreaud C, Olguin H, Arellano C, Nachar CL, Misraji A, Martinez J, Tous Preston, L., Xu, Q., Johnson, J.A., Joseph, A., Maneval, D.R., Jr., Husain, K., Reddy, G.P., Bush, C.A., Morris, J.G. Preliminary structure determination of the capsular polysaccharide of Vibrio cholerae O139 Bengal AI1837. J. Bacteriol. 1995, 177, 835-838.

Sperandio, V., J.A. Girón, W.D. Silveira and J.B. Kaper. The OmpU outer membrane protein, a potential adherence factor of Vibrio cholerae. Infection and Immunity, 1995, 63:4433-4438.

Tacket, C.O., Losonsky, G., Nataro, J.P., Wasserman, S.S., Cryz, S.J., Edelman, R., Levine, M.M. Extension of the volunteers challenge model to study South American Cholera in a population of volunteers with predominantly blood group antigen O. Trans. Roy. Soc. Trop. Med. Hyg. 1995, 89:75-77.

Tacket CO, Losonsky G, Nataro JP, Comstock L, Michalski J, Edelman R, Kaper JB, Levine MM. Initial clinical studies of CVD 112 Vibrio cholerae O139 live oral vaccine: safety and efficacy against experimental challenge. Journal of Infectious Diseases, 1995, 172, 883-886.

Tacket CO, Losonsky GA, Nataro JP, Wasserman SS, Cryz SJ, Edelman RE, Levine MM. Extension of the volunteer challenge model to study South American cholera in a population of volunteers predominantly with blood group antigen O. Trans R Soc Trop Med Hyg 89:75-77, 1995.

Fasano A, Fiorentini C, Donelli G, Kaper JG, Margaretten K, Ding X, Gandalini S, Comstock L, and Goldblum SE. Zonula occludens toxin (ZOT) modulates tight junctions through protein kinase C-dependent actin reorganization, in vitro. Journal of Clinical Investigation, 1995, 96:710-720.

Acheson DW, Levine MM, Kaper JB, Keusch GT. Protective immunity to Shiga-like toxin I following oral immunization with Shiga-like toxin I B-subunit-producing Vibrio cholerae CVD 103-HgR. Infect. Immun. 1996;64:355-357.

Comstock LE, Johnson JA, Michalski JM, Morris JG Jr, Kaper JB. Cloning and sequence of a region encoding a surface polysaccharide of Vibrio cholerae O139 and characterization of the insertion site in the chromosome of Vibrio cholerae O1. Mol. Microbiol. 1996;19:815-826.

Franco AA, Yeh PE, Johnson JA, Barry EM, Guerra H, Maurer R, Morris JG Jr. Cloning and characterization of dnaE, encoding the catalytic subunit of replicative DNA polymerase III, from Vibrio cholerae strain C6706. Gene 1996;175:281-283.

Losonsky GA, Yunyongying J, Lim V, Reymann M, Lim YL, Wasserman SS, Levine MM. Factors influencing secondary vibriocidal immune responses: relevance for understanding immunity to cholera. Infect. Immun. 1996;64:10-15.

Morris JG Jr, Sztein MB, Rice EW, Nataro JP, Losonsky GA, Panigrahi P, Tacket CO, Johnson JA. Vibrio cholerae O1 can assume a chlorine-resistant rugose survival form that is virulent for humans. J. Infect. Dis. 1996;174:1364-1368.

Silva TM, Schleupner MA, Tacket CO, Steiner TS, Kaper JB, Edelman R, Guerrant R. New evidence for an inflammatory component in diarrhea caused by selected new, live attenuated cholera vaccines and by El Tor and Q139 Vibrio cholerae. Infect. Immun. 1996;64:2362-2364.

Sperandio V, Bailey C, Giron JA, DiRita VJ, Silveira WD, Vettore AL, Kaper JB. Cloning and characterization of the gene encoding the OmpU outer membrane protein of Vibrio cholerae. Infect. Immun. 1996;64:5406-5409.

Cookson ST, Stamboulian D, Demonte J, Quero L, Martinez de Arquiza C, Aleman A, Lepetic A, Levine MM. A cost-benefit analysis of programmatic use of CVD 103-HgR live oral cholera vaccine in a high-risk population. Int. J. Epidemiol. 1997;26:212-219.

Fasano A, Uzzau S. Modulation of intestinal tight junctions by Zonula occludens toxin permits enteral administration of insulin and other macromolecules in an animal model. J. Clin. Invest. 1997;99:1158-1164.

Fasano A, Uzzau S, Fiore C, Margaretten K. The enterotoxic effect of zonula occludens toxin on rabbit small intestine involves the paracellular pathway. Gastroenterology 1997;112:839-846.

Fiore AE, Michalski JM, Russell RG, Sears CL, Kaper JB. Cloning, characterization, and chromosomal mapping of a phospholipase (lecithinase) produced by Vibrio cholerae. Infect. Immun. 1997;65:3112-3117.

Levine MM. Oral vaccines against cholera: lessons from Vietnam. and elsewhere. Lancet 1997;349:220-221.

Losonsky GA, Lim Y, Motamedi P, Comstock LE, Johnson JA, Morris JG Jr, Tacket CO, Kaper JB, Levine MM. Vibriocidal antibody responses in North American volunteers exposed to wild-type or vaccine Vibrio cholerae O139: specificity and relevance to immunity. Clin. Diagn. Lab. Immunol. 1997;4:264-269.

Tacket CO, Kotloff KL, Losonsky G, Nataro JP, Michalski J, Kaper JB, Edelman R, Levine MM. Volunteer studies investigating the safety and efficacy of live oral El Tor Vibrio cholerae O1 vaccine strain CVD 111. Am. J. Trop. Med. Hyg. 1997;56:533-537.

Taylor DN, Tacket CO, Losonsky G, Castro O, Gutierrez J, Meza R, Nataro JP, Kaper JB, Wasserman SS, Edelman R, Levine MM, Cryz SJ. Evaluation of a bivalent (CVD 103-HgR/CVD 111) live oral cholera vaccine in adult volunteers from the United States and Peru. Infect. Immun. 1997;65:3852-3856.

Trucksis M, Conn TL, Fasano A, Kaper JB. Production of Vibrio cholerae accessory cholera enterotoxin (Ace) in the yeast Pichia pastoris. Infect. Immun. 1997;65:4984-4988.

Crawford JA, Kaper JB, DiRita VJ. Analysis of ToxR-dependent transcription activation of ompU, the gene encoding a major envelope protein in Vibrio cholerae. Mol. Microbiol. 1998;29:235-46.

Karaolis DK, Johnson JA, Bailey CC, Boedeker EC, Kaper JB, Reeves PR. A Vibrio cholerae pathogenicity island associated with epidemic and pandemic strains. Proc. Natl. Acad. Sci. U .S .A .1998;95:3134-9.

Perry RT, Plowe CV, Koumare B, Bougoudogo F, Kotloff KL, Losonsky GA, Wasserman SS, Levine MM. A single dose of live oral cholera vaccine CVD 103-HgR is safe and immunogenic in HIV-infected and HIV-noninfected adults in Mali. Bull. WHO 1998;76:63-71.

Sack DA, Tacket CO, Cohen MB, Sack RB, Losonsky GA, Shimko J, Nataro JP, Edelman R, Levine MM, Giannella RA, Schiff G, Lang D. Validation of a volunteer model of cholera with frozen bacteria as the challenge. Infect. Immun. 1998;66:1968-72.

Tacket CO, Taylor RK, Losonsky G, Lim Y, Nataro JP, Kaper JB, Levine MM. Investigation of the roles of toxin-coregulated pili and mannose-sensitive hemagglutinin pili in the pathogenesis of Vibrio cholerae O139 infection. Infect. Immun. 1998;66:692-5.

Trucksis M, Michalski J, Deng YK, Kaper JB. The Vibrio cholerae genome contains two unique circular chromosomes. Proc. Natl. Acad. Sci. U.S.A. 1998;95:14464-9.

Cohen MB, Giannella RA, Losonsky GA, Lang DR, Parker S, Hawkins JA, Gunther C, Schiff GA. Validation and characterization of a human volunteer challenge model for cholera by using frozen bacteria of the new Vibrio cholerae epidemic serotype, O139. Infect. Immun. 1999;67:6346-9.

Karaolis DK, Kaper JB. Vibrio cholerae TCP: a trifunctional virulence factor?: Response. Trends Microbiol. 1999;7:393.

Karaolis DK, Somara S, Maneval DR Jr, Johnson JA, Kaper JB. A bacteriophage encoding a pathogenicity island, a type-IV pilus and a phage receptor in cholera bacteria. Nature. 1999;399:375-9.

Lagos R, Fasano A, Wasserman SS, Prado V, San Martin O, Abrego P, Losonsky GA, Alegria S, Levine MM. Effect of small bowel bacterial overgrowth on the immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR. J. Infect. Dis. 1999;180:1709-12.

Lagos R, San Martin O, Wasserman SS, Prado V, Losonsky GA, Bustamante C, Levine MM. Palatability, reactogenicity and immunogenicity of engineered live oral cholera vaccine CVD 103-HgR in Chilean infants and toddlers. Pediatr. Infect. Dis. J. 1999;18:624-30.

Marinaro M, Di Tommaso A, Uzzau S, Fasano A, De Magistris MT. Zonula occludens toxin is a powerful mucosal adjuvant for intranasally delivered antigens. Infect. Immun. 1999;67:1287-91.

Tacket CO, Cohen MB, Wasserman SS, Losonsky G, Livio S, Kotloff K, Edelman R, Kaper JB, Cryz SJ, Giannella RA, Schiff G, Levine MM. Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El Tor Inaba three months after vaccination. Infect. Immun. 1999;67:6341-5.

Taylor DN, Sanchez JL, Castro JM, Lebron C, Parrado CM, Johnson DE, Tacket CO, Losonsky GA, Wasserman SS, Levine MM, Cryz SJ. Expanded safety and immunogenicity of a bivalent, oral, attenuated cholera vaccine, CVD 103-HgR plus CVD 111, in United States military personnel stationed in Panama. Infect. Immun. 1999;67:2030-4.

Uzzau S, Cappuccinelli P, Fasano A. Expression of Vibrio cholerae zonula occludens toxin and analysis of its subcellular localization. Microb Pathog. 1999;27:377-85.

Cooper PJ, Chico ME, Losonsky G, Sandoval C, Espinel I, Sridhara R, Aguilar M, Guevara A, Guderian RH, Levine MM, Griffin GE, Nutman TB. Albendazole treatment of children with ascariasis enhances the vibriocidal antibody response to the live attenuated oral cholera vaccine CVD 103-HgR. J Infect Dis. 2000, 182:1199-206.

Li CC, Crawford JA, DiRita VJ, Kaper JB. Molecular cloning and transcriptional regulation of ompT, a ToxR-repressed gene in Vibrio cholerae. Mol Microbiol. 2000, 35:189-203.

Richie EE, Punjabi NH, Sidharta YY, Peetosutan KK, Sukandar MM, Wasserman SS, Lesmana MM, Wangsasaputra FF, Pandam SS, Levine MM, O'Hanley PP, Cryz SJ, Simanjuntak CH. Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area. Vaccine. 2000, 18:2399-410.

Trucksis M, Conn TL, Wasserman SS, Sears CL. Vibrio cholerae ACE stimulates Ca(2+)-dependent Cl(-)/HCO(3)(-) secretion in T84 cells in vitro. Am J Physiol Cell Physiol. 2000, 279:C567-77.

Cooper PJ, Chico M, Sandoval C, Espinel I, Guevara A, Levine MM, Griffin GE, Nutman TB. Human infection with Ascaris lumbricoides is associated with suppression of the interleukin-2 response to recombinant cholera toxin B subunit following vaccination with the live oral cholera vaccine CVD 103-HgR. Infection and Immunity. 2001, 69:1574-1580.

Merrell DS, Bailey C, Kaper JB, Camilli A The ToxR-Mediated Organic Acid Tolerance Reponse of Vibrio cholerae Requires OmpU Journal of Bacteriology 2001 183 2746-2754 Cholera

Okeke IN, Eardley J, Bailey CC, Kaper JB. Vibrio cholerae. In, Molecular Medical Microbiology. 2002. pp. 1191-1236.

Li CC, Merrell DS, Camilli A, Kaper JB. ToxR interferes with CRP-dependent transcriptional activation of ompT in Vibrio cholerae. Molecular Microbiology. 2002, 43:1577-1589.

McCardell BA, Sathyamoorthy V, Michalski J, Lavu S, Kothary M, Livezey J, Kaper JB, Hall R. Cloning, expression and characterization of the CHO cell elongating factor (Cef) from Vibrio cholerae 01. Microbial Pathogenesis. 2002, 32:165-172.